ILIAD Biotechnologies

Executive Summary

ILIAD Biotechnologies is a clinical-stage biotechnology company dedicated to preventing and treating Bordetella pertussis infections. Its lead candidate, BPZE1, is a next-generation pertussis vaccine that has successfully completed two Phase 2 clinical trials, demonstrating safety and immunogenicity. The company aims to address the limitations of current acellular vaccines, which have waning efficacy and fail to prevent transmission. BPZE1 is designed as a live attenuated intranasal vaccine that mimics natural infection to induce broad mucosal and systemic immunity. With pertussis cases rising globally, ILIAD's vaccine could become a critical public health tool. The company is based in San Diego and was founded in 2016, advancing toward pivotal trials.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 Trial for BPZE170% success
• H1 2027Partnership or Licensing Deal for BPZE160% success
• Q2 2026Publication of Phase 2b Efficacy Data80% success